INSUBCONTINENT EXCLUSIVE:
to Rs 123 crore in the corresponding period last year
The Bengaluru-based company's revenue during the March quarter grew 26 per cent to Rs 2,044 crore, tracking higher growth in its
biosimilar, research services, and generic business
Biocon is involved in manufacturing generic active pharmaceutical ingredients and is an innovation-led integrated company.According to a
regulatory filing by the firm to the BSE on Thursday, April 29, Biocon's consolidated revenue increased 26 per cent in the fourth quarter
of the fiscal 2020-21 to Rs 2,044 crore, compared to Rs 1,621 crore in the corresponding quarter last year.Amid the second wave of the
COVID-19 pandemic in the country, the company's subsidiary Biocon Biologics, stepped up to provide the anti-CD6 novel biologic Itolizumab
due to the uncertainty of the second wave of the pandemic and considering the investments in R-D, the board of directors decided not to
After reporting the March quarter results, the share price of Biocon Limited edged marginally higher
Shares of Biocon settled 0.77 per cent higher at Rs 393.95 apiece on the BSE
